Marshall Wace
ALBO

Marshall Wace’s Albireo Pharma Inc ALBO Stock Holding History

Marshall Wace’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-129,126
Closed -$3.01M – 4297
2021
Q4 		$3.01M Sell
129,126
-89,833
-41% -$2.39M 0.01% 1778
2021
Q3 		$6.83M Sell
218,959
-40,948
-16% -$1.27M 0.03% 776
2021
Q2 		$9.14M Sell
259,907
-220,160
-46% -$7.16M 0.04% 525
2021
Q1 		$16.9M Sell
480,067
-187,636
-28% -$6.93M 0.08% 262
2020
Q4 		$25M Sell
667,703
-25,832
-4% -$939K 0.14% 157
2020
Q3 		$23.1M Buy
693,535
+608,709
+718% +$17.7M 0.15% 144
2020
Q2 		$2.25M Buy
+84,826
New +$2M 0.02% 746
2020
Q1 		– Sell
-9,655
Closed -$246K – 2189
2019
Q4 		$246K Buy
9,655
+7,772
+413% +$155K ﹤0.01% 1311
2019
Q3 		$38K Buy
+1,883
New +$48.7K ﹤0.01% 1531
2019
Q2 		– Sell
-1,883
Closed -$61K – 1979
2019
Q1 		$61K Hold
1,883
– – ﹤0.01% 1504
2018
Q4 		$46K Buy
+1,883
New +$49.8K ﹤0.01% 1453

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Marshall Wace's ALBO Position: Q1 2022 in Review

Marshall Wace sold out of Albireo Pharma Inc (ALBO) in Q1 2022, closing a stake of 129,126 shares — an estimated $3.01M sold.

Marshall Wace first reported a position in ALBO in Q4 2018 and held it in 11 quarters. The position peaked at $25M in Q4 2020. 109 funds tracked by Wall St. Rank hold ALBO as of Q1 2022.

  • Marshall Wace reported no remaining Albireo Pharma Inc position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 129,126 Albireo Pharma Inc shares in Q1 2022, an estimated $3.01M.
  • Marshall Wace first reported a position in Albireo Pharma Inc in Q4 2018 and held it in 11 quarters.
  • Marshall Wace's Albireo Pharma Inc position peaked at $25M in Q4 2020.
  • 109 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.